The CSO at Aptamer group spoke recently in an interview with BioPharma APAC about Neuro-Bio’s ongoing partnership in which to develop Optimer binders to enable a lateral flow test for the early detection of Alzheimer’s disease. He also covered how a move away from traditional antibodies to more tuneable binders like Optimer technology is enabling improved diagnostic accuracy and development and how post-pandemic Optimer is helping side-step global logistical challenges.

We are grateful for Aptamer Group and being able to work together to try and help millions of people globally suffering from this cruel disease.

Click here to read more